Ghent University Academic Bibliography

Miscellaneous
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).

Add to list

Journal Article
A1
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491

Add to list

Journal Article
A1
open access

TARP as antigen in cancer immunotherapy

Jolien Vanhooren (UGent) , Charlotte Derpoorter (UGent) , Barbara Depreter, Larissa Deneweth (UGent) , Jan Philippé (UGent) , Barbara De Moerloose (UGent) and Tim Lammens (UGent)

(2021) CANCER IMMUNOLOGY IMMUNOTHERAPY. 70. p.3061-3068

Add to list

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen, Vibeke Kruse (UGent) , Jurgen Corthals, Kelly Schats, Pieter-Jan van Dam, Teofila Seremet, Carlo Heirman, Lieve Brochez (UGent) , Mark Kockx, Kris Thielemans, et al.

(2020) CANCER IMMUNOLOGY IMMUNOTHERAPY. 69(12). p.2589-2598

Add to list

Journal Article
A1
open access

Deciphering myeloid-derived suppressor cells : isolation and markers in humans, mice and non-human primates

Luca Cassetta, Espen S. Baekkevold, Sven Brandau, Anna Bujko (UGent) , Marco A. Cassatella, Anca Dorhoi, Carsten Krieg, Ang Lin, Karin Lore, Olivia Marini, et al.

(2019) CANCER IMMUNOLOGY IMMUNOTHERAPY. 68(4). p.687-697

Add to list

Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice

Sofie Denies (UGent) , Bregje Leyman (UGent) , Hanne Huysmans, Francis Combes (UGent) , Séan Mc Cafferty (UGent) , Laetitia Cicchelero (UGent) , Marjan Steppe, Joyca De Temmerman and Niek Sanders (UGent)

(2017) CANCER IMMUNOLOGY IMMUNOTHERAPY. 66(12). p.1545-1555

Add to list

The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression

Aline Van Acker (UGent) , Els Louagie (UGent) , Jessica Filtjens (UGent) , Sylvie Taveirne (UGent) , Els Van Ammel (UGent) , Tessa Kerre (UGent) , Dirk Elewaut (UGent) , Tom Taghon (UGent) , Bart Vandekerckhove (UGent) , Jean Plum (UGent) , et al.

(2016) CANCER IMMUNOLOGY IMMUNOTHERAPY. 65(11). p.1365-1375

Add to list

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

Sandra Van Lint (UGent) , Sofie Wilgenhof, Carlo Heirman, Jurgen Corthals, Karine Breckpot, Aude Bonehill, Bart Neyns and Kris Thielemans

(2014) CANCER IMMUNOLOGY IMMUNOTHERAPY. 63(9). p.959-967

Add to list

Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin

Abhishek D Garg, Dmitri Krysko (UGent) , Peter Vandenabeele (UGent) and Patrizia Agostinis

(2012) CANCER IMMUNOLOGY IMMUNOTHERAPY. 61(2). p.215-221

Add to list

Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.

Sonja Verheyden, Soldano Ferrone, Arend Mulder, Frans Claas, Rik Schots, Barbara De Moerloose (UGent) , Yves Benoit and Christian Demanet

(2009) CANCER IMMUNOLOGY IMMUNOTHERAPY. 58(6). p.855-865

Academic Bibliography

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

TARP as antigen in cancer immunotherapy

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Deciphering myeloid-derived suppressor cells : isolation and markers in humans, mice and non-human primates

Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice

The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin

Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.

Contents

Support

Contact